Find Reports
Select Report Type
Reimbursement Review
Displaying 101 - 125 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| infliximab | Remsima | infliximab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0816-001 | |||
| maralixibat | Livmarli | maralixibat | Alagille syndrome | Reimburse with clinical criteria and/or conditions | Complete | SR0780-000 | |||
| etranacogene dezaparvovec | Hemgenix | etranacogene dezaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Complete | SG0805-000 | |||
| everolimus | N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis | Reimburse with clinical criteria and/or conditions | Complete | SX0814-000 | |||
| panitumumab | N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Complete | PX0333-000 | |||
| cannabidiol | Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Reimburse with clinical criteria and/or conditions | Complete | SR0800-000 | |||
| cannabidiol | Epidiolex | cannabidiol | Dravet Syndrome (DS) | Reimburse with clinical criteria and/or conditions | Complete | SR0799-000 | |||
| cannabidiol | Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Reimburse with clinical criteria and/or conditions | Complete | SR0798-000 | |||
| nirmatrelvir/ritonavir | Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Reimburse with clinical criteria and/or conditions | Complete | SR0808-000 | |||
| HR positive, HER2 negative bre... | HR positive, HER2 negative breast cancer | Complete | PH0041-000 | ||||||
| Large B cell lymphoma | Large B cell lymphoma | Complete | PH0040-000 | ||||||
| teclistamab | Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | PC0332-000 | |||
| Prostate Cancer | Prostate Cancer | Completed | PH0039-000 | ||||||
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | Complete | PH0038-000 | ||||||
| drospirenone | Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Complete | SR0806-000 | |||
| ravulizumab | Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Complete | SR0785-000 | |||
| inebilizumab | Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Complete | SR0793-000 | |||
| trifluridine and tipiracil | Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0330-000 | |||
| sotorasib | Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Complete | PC0300-000 | |||
| treosulfan | Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Complete | PC0324-000 | |||
| Renal cell carcinoma | Renal cell carcinoma | Complete | PH0037-000 | ||||||
| fidanacogene elaparvovec | Beqvez | fidanacogene elaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Complete | SG0802-000 | |||
| belumosudil | Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0789-000 | |||
| odevixibat | Bylvay | odevixibat | Progressive familial intrahepatic cholestasis (PFIC) | Reimburse with clinical criteria and/or conditions | Complete | SR0788-000 | |||
| nivolumab and relatlimab | Opdualag | nivolumab and relatlimab | unresectable or metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0329-000 |
Health Technology Review
Displaying 101 - 125 of 602
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Long-Term Use of Omalizumab for the Treatment of Chronic Idiopathic Urticaria | Systematic Review | Active | RE0043-000 | |||
| SGLT2 inhibitors for the treatment of type 2 diabetes | Technology Review | Cancelled | HC0049-000 | |||
| Renal Denervation | Rapid Review | Completed | RC1532-000 | |||
| Long-Term Use of Omalizumab for Chronic Idiopathic Urticaria | Technology Review | Completed | HC0053-000 | |||
| Patterns in Utilization of Long-Acting Inhaled Drugs for the Treatment of Chronic Obstructive Pulmonary Disease | Technology Review | In Progress | HC0086 -000 | |||
| NovoTTF-200A | Optimal Use | Completed | OP0554-000 | |||
| Utilization Analysis of Tofacitinib and Other Drugs Among Individuals With Ulcerative Colitis: Feasibility Analysis | Observational Study | Complete | OS0003-000 | |||
| Reprocessed Single-Use Semicritical and Critical Medical Devices | We sought to identify and summarize literature evaluating the clinical safety of reprocessed single-used medical devices (SUMDs), defined as infections, mortality, or other adverse events, compared with nonreprocessed (new) SUMDs. | Rapid Review | Completed | RC1511-000 | ||
| Aerosol Therapy With Inhalers During Mechanical Ventilation | Rapid Review | Completed | RC1529-000 | |||
| Pan- Canadian Rare Disease Registries | Environmental Scan | Completed | ES0369-000 | |||
| Ketamine for Adults With Substance Use Disorders | To inform decisions about using ketamine for treating SUDs, we sought to identify and summarize the literature comparing the clinical and cost-effectiveness of ketamine with placebo or no treatment, with alternative interventions, or among ketamine administered via different routes for SUDs. | Rapid Review | Completed | RC1523-000 | ||
| Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle | Rapid Review | Completed | RC1528-000 | |||
| Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery | Rapid Review | Completed | RC1530-000 | |||
| Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults | Technology Review | Completed | HE0047 -000 | |||
| Timing of Antibiotic Therapy for Neisseria Gonorrhoeae Infection | Rapid Review | Completed | RC1527-000 | |||
| Clinical and Instrumental Swallowing Assessments for Dysphagia | Rapid Review | Completed | RC1526-000 | |||
| Average Volume of MRI Exams Conducted per Hour Across Canada | Using data from the national Canadian Medical Imaging Inventory 2019 to 2020 survey, we calculated an average of MRI exams performed per hour across Canada | CMII Service | Completed | CM0008-000 | ||
| Biologic Drugs for Severe Asthma | Technology Review | Completed | RE0047-000 | |||
| Buprenorphine Formulations for Opioid Use Disorder | Systematic Review | Completed | RE0051-000 | |||
| The Safety of Niraparib in Ovarian Cancer | To give clinicians and policy-makers a better understanding of the niraparib’s risk profile, researchers conducted an observational study to look at how the safety and tolerability of niraparib in the real world compares with observations from seminal clinical trials. | Observational Study | Active | OS0002-000 | ||
| Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update | We conducted a review of the clinical effectiveness, cost-effectiveness, and evidence-based guidelines on the use of ketamine in adults with TRD or PTSD, to help guide decisions on the use of ketamine for managing these conditions. | Rapid Review | Completed | RC1522-000 | ||
| Endobronchial Valves for the Management of Severe Emphysema | Rapid Review | Completed | RC1524-000 | |||
| Ketorolac for Renal Colic | Rapid Review | Completed | RC1525-000 | |||
| Immune checkpoint inhibitors for mutated non–small cell lung cancer | Observational Study | In Progress | OS0008-000 | |||
| Leucovorin Dosing for Gastrointestinal Cancer | Rapid Review | Completed | RC1518-000 |
Horizon Scan
Displaying 101 - 110 of 110
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|
| Dementia Villages: Innovative Residential Care for People With Dementia | EH0071-000 | |||||
| Dementia Villages | Emerging Health Technologies | Completed | EH0071-000 | |||
| Dementia Villages - Position Statement | EH0071-000 | |||||
| Health Technology Update — Issue 24 | Health Technology Update | Completed | EN0014-000 | |||
| Esketamine for Treatment-Resistant Depression | EH0075-000 | |||||
| Horizon Scan Roundup — 2018 | ER0007-000 | |||||
| Health Technology Update — Issue 23 | Health Technology Update | Completed | EN0013-000 | |||
| An Overview of Clinical Applications of Artificial Intelligence | Emerging Health Technologies | Completed | EH0070-000 | |||
| Alternating Electric Fields ("Tumour- Treating Fields") for the Treatment of Glioblastoma | Emerging Health Technologies | Completed | EH0060-000 | |||
| Buprenorphine Implant for the Treatment of Opioid Use Disorder | Completed | EH0044-000 |
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 101 - 125 of 2138
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Utilization of Antidiabetic Drugs During Pregnancy | Health Technology Review | Technology Review | Active | HC0083-000 — OS0007-000 | |||
| Aripiprazole | Reimbursement Review | Received | SX0756-000 | ||||
| fruquintinib | Reimbursement Review | Complete | PC0352-000 | ||||
| Non-small-cell lung cancer (NSCLC) | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0071-000 | |||
| Myelofibrosis | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0069-000 | |||
| trametinib | Reimbursement Review | Complete | PX0372-000 | ||||
| roflumilast | Reimbursement Review | Pending | SR0887-000 | ||||
| Appropriate Use of Antipsychotics in Long-Term Care | Health Technology Review | Technology Review | Active | HC0095-000 | |||
| trastuzumab deruxtecan | Reimbursement Review | Pending | PC0401-000 | ||||
| ciltacabtagene autoleucel | Reimbursement Review | Complete | PG0361-000 | ||||
| lisocabtagene maraleucel | Reimbursement Review | Complete | PG0358-000 | ||||
| Urothelial carcinoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0070-000 | |||
| Midline Catheters for Administering Intravenous Infusion Therapy | Health Technology Review | Rapid Review | Completed | RC1572-000 | |||
| Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis | Health Technology Review | Technology Review | Completed | HC0081-000 | |||
| tarlatamab | Reimbursement Review | Active | PC0351-000 | ||||
| upadacitinib | Reimbursement Review | Pending | SR0877-000 | ||||
| Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis | Health Technology Review | Peer-reviewed Summary with Critical Appraisal | Completed | RD0071-000 | |||
| Cladribine and Natalizumab for Relapsing-Remitting Multiple Sclerosis | Reimbursement Review | Streamlined Drug Class Review | Active | TS0004-000 | |||
| cladribine | Reimbursement Review | Complete | SR0546-000 | ||||
| venetoclax | Reimbursement Review | Complete | PC0362-000 | ||||
| Natalizumab | Reimbursement Review | Complete | SR0133-000 | ||||
| Multiple Myeloma | Reimbursement Review | Provisional Funding Algorithm | Active | PH0068-000 | |||
| inebilizumab | Reimbursement Review | Pending | SR0889-000 | ||||
| vanzacaftor, tezacaftor, deutivacaftor | Reimbursement Review | Pending | SR0896-000 | ||||
| Trends in Opioid Prescribing in Canada, 2018-2022 | This study analyzed trends in prescription opioid use for pain and opioid agonist therapy from January 2018 to December 2022 across 6 Canadian provinces. | Health Technology Review | Technology Review | Completed | HC0071-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81